Multihance

Active Ingredient:: Gadobenate Dimeglumine
Origin:: EU

Multihance (Gadobenate Dimeglumine)

Q: What is Multihance used for?

Multihance is an intravenous gadolinium‑based contrast agent used to improve the quality of magnetic resonance imaging. It is indicated for MRI examinations of the central nervous system, liver, cardiovascular system, and for magnetic resonance angiography, helping clinicians visualize anatomy and pathology more clearly.

Q: How does Gadobenate dimeglumine work?

Gadobenate dimeglumine is a paramagnetic chelate that shortens the T1 relaxation time of nearby water protons when injected. This creates a higher signal on T1‑weighted MRI sequences, enhancing the contrast between normal and abnormal tissues and allowing more precise imaging of organs and vessels.

Q: What is the usual dose of Multihance?

The dose of Multihance is determined by the prescribing physician based on the patient’s weight, the specific imaging study, and renal function. The product label recommends a dose calculated on a per‑kilogram basis, and the exact amount is set by the ordering clinician.

Q: Is Multihance safe in pregnancy or while breastfeeding?

The pregnancy category for Gadobenate dimeglumine is listed as unknown, meaning safety data are limited. It should only be used during pregnancy when the diagnostic benefit outweighs potential risk. For breastfeeding, limited information is available; clinicians should weigh benefits against possible exposure to the infant.

Q: How do I order Multihance from GNH India?

To order Multihance, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Q: How does Multihance compare with other gadolinium contrast agents?

Multihance (gadobenate dimeglumine) offers a higher relaxivity than many older agents, providing stronger signal enhancement at lower doses. Compared with agents such as gadobutrol (Gadavist), Multihance may deliver comparable image quality with a slightly different safety profile, particularly regarding renal considerations and the rare risk of NSF.

Q: What are the storage and handling requirements for Multihance?

Multihance should be stored refrigerated between 2 °C and 8 °C. Protect the vial from light, do not freeze, and avoid shaking the solution. If the product reaches room temperature, it may be used within a limited time as specified in the manufacturer’s instructions.

Q: How is Multihance administered?

Multihance is administered by intravenous injection, typically using a power injector to deliver a controlled bolus. The injection is performed under the supervision of a qualified healthcare professional, and the patient is monitored for any immediate reactions during and after the administration.

Q: What are the most serious risks associated with Multihance?

The most serious risks include severe allergic reactions such as anaphylaxis, nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment, sudden hypotension, and cardiac arrhythmias. Prompt recognition and management of these events are essential, and patients with high risk should be evaluated carefully before use.

Q: Who should not use Multihance?

Multihance should be avoided in patients with known hypersensitivity to gadolinium‑based agents, those with severe renal dysfunction (e.g., GFR <30 mL/min/1.73 m²) due to the risk of NSF, and in individuals who have experienced prior severe reactions to contrast media. Clinical judgment is required for all other contraindications.

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium-based contrast agent presented as a 0.5 mmol/mL injectable solution for intravenous use. It enhances magnetic resonance imaging of specific organs and vascular structures in patients undergoing diagnostic scans.

GNH India supplies Multihance as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bracco Imaging S.P.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Multihance is used as a gadolinium‑based contrast agent for magnetic resonance imaging of several organ systems.

Central nervous system MRI: improves lesion detection and delineation by increasing signal intensity on T1‑weighted images.
Liver MRI: enhances detection and characterization of focal liver lesions, including hepatocellular carcinoma.
Cardiovascular MRI: provides high‑resolution images of cardiac chambers, myocardium, and vascular anatomy.
Magnetic resonance angiography (MRA): facilitates visualization of arterial and venous structures with improved contrast.

How It Works

Gadobenate dimeglumine is a paramagnetic gadolinium chelate that, when administered intravenously, distributes into the extracellular fluid and shortens the T1 relaxation time of nearby water protons. This effect increases signal intensity on T1‑weighted MRI sequences, allowing clearer differentiation of tissues and vascular structures during imaging examinations.

Side Effects

Adverse reactions to Multihance are generally related to its intravenous administration and the gadolinium chelate.

Common Side Effects

Nausea: mild, transient feeling of stomach upset.
Headache: brief, mild to moderate intensity.
Injection site discomfort: pain or burning at the infusion site.
Warm sensation: transient feeling of warmth or flushing.

Serious or Rare Side Effects

Allergic reaction: urticaria, rash, or anaphylaxis requiring emergency care.
Nephrogenic systemic fibrosis (NSF): rare fibrotic disorder in patients with severe renal impairment.
Severe hypotension: sudden drop in blood pressure following injection.
Cardiac arrhythmia: irregular heart rhythm observed in susceptible individuals.

Precautions & Warnings

When using Multihance, several safety considerations should be observed.

Renal function assessment: evaluate kidney function before administration, especially in patients with GFR <30 mL/min/1.73 m².
History of hypersensitivity: review prior reactions to gadolinium agents or contrast media.
Pregnancy: use only if clearly needed, as safety data are limited.
Breastfeeding: consider risk/benefit; limited data on excretion in milk.
Concomitant nephrotoxic drugs: monitor closely when used with agents that may affect renal function.
Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Multihance may interact with other medicines; awareness of the interaction level is important.

Major Interactions (Avoid)

Severe renal impairment agents: co‑administration with other gadolinium agents increases risk of NSF.
High‑dose calcium supplements: may interfere with gadolinium binding, potentially increasing free gadolinium.
Iron chelators: can displace gadolinium from its chelate, raising toxicity risk.

Moderate Interactions (Monitor Closely)

Loop diuretics: may affect renal clearance, requiring monitoring of kidney function.
ACE inhibitors/ARBs: combined effect on renal perfusion may necessitate closer observation.
Antihistamines: may mask early signs of an allergic reaction, requiring vigilance.

Frequently Asked Questions

Multihance is an intravenous gadolinium‑based contrast agent used to improve the quality of magnetic resonance imaging. It is indicated for MRI examinations of the central nervous system, liver, cardiovascular system, and for magnetic resonance angiography, helping clinicians visualize anatomy and pathology more clearly.

Gadobenate dimeglumine is a paramagnetic chelate that shortens the T1 relaxation time of nearby water protons when injected. This creates a higher signal on T1‑weighted MRI sequences, enhancing the contrast between normal and abnormal tissues and allowing more precise imaging of organs and vessels.

The dose of Multihance is determined by the prescribing physician based on the patient’s weight, the specific imaging study, and renal function. The product label recommends a dose calculated on a per‑kilogram basis, and the exact amount is set by the ordering clinician.

The pregnancy category for Gadobenate dimeglumine is listed as unknown, meaning safety data are limited. It should only be used during pregnancy when the diagnostic benefit outweighs potential risk. For breastfeeding, limited information is available; clinicians should weigh benefits against possible exposure to the infant.

To order Multihance, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Multihance (gadobenate dimeglumine) offers a higher relaxivity than many older agents, providing stronger signal enhancement at lower doses. Compared with agents such as gadobutrol (Gadavist), Multihance may deliver comparable image quality with a slightly different safety profile, particularly regarding renal considerations and the rare risk of NSF.

Multihance should be stored refrigerated between 2 °C and 8 °C. Protect the vial from light, do not freeze, and avoid shaking the solution. If the product reaches room temperature, it may be used within a limited time as specified in the manufacturer’s instructions.

Multihance is administered by intravenous injection, typically using a power injector to deliver a controlled bolus. The injection is performed under the supervision of a qualified healthcare professional, and the patient is monitored for any immediate reactions during and after the administration.

The most serious risks include severe allergic reactions such as anaphylaxis, nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment, sudden hypotension, and cardiac arrhythmias. Prompt recognition and management of these events are essential, and patients with high risk should be evaluated carefully before use.

Multihance should be avoided in patients with known hypersensitivity to gadolinium‑based agents, those with severe renal dysfunction (e.g., GFR <30 mL/min/1.73 m²) due to the risk of NSF, and in individuals who have experienced prior severe reactions to contrast media. Clinical judgment is required for all other contraindications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 16 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.